MRF-Logo2019-Horizontal-RGB
Nivolumab as first-line treatment
REGISTER
The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Content within the patient forum is user-generated and has not been reviewed by medical professionals. Other sections of the Melanoma Research Foundation website include information that has been reviewed by medical professionals as appropriate. All medical decisions should be made in consultation with your doctor or other qualified medical professional.

Nivolumab as first-line treatment

› Forums › General Melanoma Community › Nivolumab as first-line treatment

  • Post
Viewing 5 reply threads
  • Replies
      • July 1, 2014 at 12:38 pm
      mary1233
      Participant

        What is even more exciting about this trial is that the wild type mutations were specifically randomized. The wild types have just started to become part of the clinical trials, and here we have one that worked so well that they stopped it early.

        When I was diagnosed in 2012 with wild type mucosal melanoma my doctor offered me a chemo treatment that had been part of a very small study in China. He said he did not know if it would work, but that if I had come in six months earlier, he would have had no ajuvant options to offer me.

        My how things have change.

        Good luck to all.

         

        • July 1, 2014 at 12:38 pm
        mary1233
        Participant

          What is even more exciting about this trial is that the wild type mutations were specifically randomized. The wild types have just started to become part of the clinical trials, and here we have one that worked so well that they stopped it early.

          When I was diagnosed in 2012 with wild type mucosal melanoma my doctor offered me a chemo treatment that had been part of a very small study in China. He said he did not know if it would work, but that if I had come in six months earlier, he would have had no ajuvant options to offer me.

          My how things have change.

          Good luck to all.

           

          • July 1, 2014 at 12:38 pm
          mary1233
          Participant

            What is even more exciting about this trial is that the wild type mutations were specifically randomized. The wild types have just started to become part of the clinical trials, and here we have one that worked so well that they stopped it early.

            When I was diagnosed in 2012 with wild type mucosal melanoma my doctor offered me a chemo treatment that had been part of a very small study in China. He said he did not know if it would work, but that if I had come in six months earlier, he would have had no ajuvant options to offer me.

            My how things have change.

            Good luck to all.

             

              • July 1, 2014 at 6:13 pm
              Ninniditti
              Participant

                Hi, I just wonder which chemo treatment  you got and did it work?  I also have mucosal melanoma and have no treatments left. 

                • September 10, 2014 at 2:46 am
                JerryfromFauq
                Participant

                  Did they sequence your tumor or just run specific tests on it?   Sequencung costs a l ot more but finds new mutations that they didn't know were assiciateds with many types of specific cancers.  Finding the dorrect rare myuttion can maake a big difference.

                   

                  • September 10, 2014 at 2:46 am
                  JerryfromFauq
                  Participant

                    Did they sequence your tumor or just run specific tests on it?   Sequencung costs a l ot more but finds new mutations that they didn't know were assiciateds with many types of specific cancers.  Finding the dorrect rare myuttion can maake a big difference.

                     

                    • September 10, 2014 at 2:46 am
                    JerryfromFauq
                    Participant

                      Did they sequence your tumor or just run specific tests on it?   Sequencung costs a l ot more but finds new mutations that they didn't know were assiciateds with many types of specific cancers.  Finding the dorrect rare myuttion can maake a big difference.

                       

                      • July 1, 2014 at 6:13 pm
                      Ninniditti
                      Participant

                        Hi, I just wonder which chemo treatment  you got and did it work?  I also have mucosal melanoma and have no treatments left. 

                        • July 1, 2014 at 6:13 pm
                        Ninniditti
                        Participant

                          Hi, I just wonder which chemo treatment  you got and did it work?  I also have mucosal melanoma and have no treatments left. 

                        • September 10, 2014 at 2:59 am
                        JerryfromFauq
                        Participant

                          Glad to see more "Wild Type" Genes being included in triaals.  Of course 'Wild Type" has limited meaning since it just mean that a specific mutation tested for within a specific gene was not found. It is not a subset in the KNOWN mutatioins for a gene, nor necessarily any mutation in a particular gene. .   Doesn't even mean that a common melanoma gene did not have a different mutation than the "common" tested for that paricular gene.  I.E. Wild Type of (BRAF, kIT, NRAS, ect0  "does not even mean that ones tumors does not still have a mutation in those particular genes (BRAF, kIT, NRAS, ect, just that they didn't have the tested for mutation,

                          • September 10, 2014 at 2:59 am
                          JerryfromFauq
                          Participant

                            Glad to see more "Wild Type" Genes being included in triaals.  Of course 'Wild Type" has limited meaning since it just mean that a specific mutation tested for within a specific gene was not found. It is not a subset in the KNOWN mutatioins for a gene, nor necessarily any mutation in a particular gene. .   Doesn't even mean that a common melanoma gene did not have a different mutation than the "common" tested for that paricular gene.  I.E. Wild Type of (BRAF, kIT, NRAS, ect0  "does not even mean that ones tumors does not still have a mutation in those particular genes (BRAF, kIT, NRAS, ect, just that they didn't have the tested for mutation,

                            • September 10, 2014 at 2:59 am
                            JerryfromFauq
                            Participant

                              Glad to see more "Wild Type" Genes being included in triaals.  Of course 'Wild Type" has limited meaning since it just mean that a specific mutation tested for within a specific gene was not found. It is not a subset in the KNOWN mutatioins for a gene, nor necessarily any mutation in a particular gene. .   Doesn't even mean that a common melanoma gene did not have a different mutation than the "common" tested for that paricular gene.  I.E. Wild Type of (BRAF, kIT, NRAS, ect0  "does not even mean that ones tumors does not still have a mutation in those particular genes (BRAF, kIT, NRAS, ect, just that they didn't have the tested for mutation,

                                • September 10, 2014 at 5:48 am
                                JerryfromFauq
                                Participant

                                  An example of the differing mutations within a known gene is given here for the Kit mutation that my melanoma tumors contain.  This also shows how some cancerous tumors that have a mutation in: 

                                  Mutations in the exons 11, 9 and rarely 13 and 17 of the c-kit gene are known to occur in GIST. The tyrosine kinase function of c-kit is important in the medical therapy for GISTs, as described below.

                                  • KIT-D816V point mutations in c-kit exon 17 are responsible for resistance to targeted therapy drugs like imatinib mesylate, a tyrosine kinase inhibitor.

                                  • KIT-p.D419del (exon 8) – A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del).[8]

                                   

                                  • September 10, 2014 at 5:48 am
                                  JerryfromFauq
                                  Participant

                                    An example of the differing mutations within a known gene is given here for the Kit mutation that my melanoma tumors contain.  This also shows how some cancerous tumors that have a mutation in: 

                                    Mutations in the exons 11, 9 and rarely 13 and 17 of the c-kit gene are known to occur in GIST. The tyrosine kinase function of c-kit is important in the medical therapy for GISTs, as described below.

                                    • KIT-D816V point mutations in c-kit exon 17 are responsible for resistance to targeted therapy drugs like imatinib mesylate, a tyrosine kinase inhibitor.

                                    • KIT-p.D419del (exon 8) – A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del).[8]

                                     

                                    • September 10, 2014 at 5:48 am
                                    JerryfromFauq
                                    Participant

                                      An example of the differing mutations within a known gene is given here for the Kit mutation that my melanoma tumors contain.  This also shows how some cancerous tumors that have a mutation in: 

                                      Mutations in the exons 11, 9 and rarely 13 and 17 of the c-kit gene are known to occur in GIST. The tyrosine kinase function of c-kit is important in the medical therapy for GISTs, as described below.

                                      • KIT-D816V point mutations in c-kit exon 17 are responsible for resistance to targeted therapy drugs like imatinib mesylate, a tyrosine kinase inhibitor.

                                      • KIT-p.D419del (exon 8) – A subset of gastrointestinal stromal tumors previously regarded as wild-type tumors carries somatic activating mutations in KIT exon 8 (p.D419del).[8]

                                       

                                Viewing 5 reply threads
                                • You must be logged in to reply to this topic.
                                About the MRF Patient Forum

                                The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

                                The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

                                Popular Topics